The sector-specific headwinds are expected to inflate operational and credit costs for microfinanciers in the medium term, Ind-Ra said. The rating agency expects asset quality stress for micro finance companies to continue in the near term with tightening of funding by banks and capital raising constraints expected to add to the challenges of the sector.
5 pharma stks with upside potential of up to 12%
Nifty Pharma index has moved in tandem with the headline index, with nearly 5% returns in the last month, with stocks gaining by up to
June 12, 2025